In 2018, Scott et al. defined a clinically and biologically distinct subgroup of tumors within GCB DLBCL characterized by a gene expression signature of HGBL-DH/TH-BCL2 [11]. Here, BCL2 is linked to diffuse large B-cell lymphoma.